$PLX
Protalix BioTherapeutics, Inc.

2012 Q3 Form 10-Q Financial Statement

#000114420412042862 Filed on August 03, 2012

View on sec.gov

Income Statement

Concept 2012 Q3 2012 Q2 2011 Q2
Revenue $3.724M $26.11M $764.0K
YoY Change 228.98% 3317.93% 25.25%
Cost Of Revenue $2.367M $3.279M $132.0K
YoY Change 975.91% 2384.09%
Gross Profit $3.023M $21.98M -$4.750M
YoY Change 346.53% -562.72% -878.69%
Gross Profit Margin 81.18% 84.17% -621.73%
Selling, General & Admin $2.220M $3.500M $1.800M
YoY Change 45.1% 94.44% 41.73%
% of Gross Profit 73.44% 15.92%
Research & Development $8.326M $10.54M $8.768M
YoY Change -10.86% 20.26% -15.26%
% of Gross Profit 275.42% 47.97%
Depreciation & Amortization $910.0K $930.0K $920.0K
YoY Change 1.11% 1.09% 21.05%
% of Gross Profit 30.1% 4.23%
Operating Expenses $8.326M $10.54M $8.768M
YoY Change -10.86% 20.26% -15.26%
Operating Profit -$5.560M $9.620M -$13.87M
YoY Change -36.58% -169.37% 42.43%
Interest Expense $20.00K $180.0K
YoY Change -88.89% 63.64%
% of Operating Profit 0.21%
Other Income/Expense, Net $81.00K $22.00K
YoY Change
Pretax Income -$5.480M $9.640M -$13.69M
YoY Change -38.29% -170.42% 36.35%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$5.479M $9.642M -$13.69M
YoY Change -38.26% -170.44% 36.34%
Net Earnings / Revenue -147.13% 36.92% -1791.75%
Basic Earnings Per Share $0.11 -$0.16
Diluted Earnings Per Share -$0.60 $0.10 -$0.16
COMMON SHARES
Basic Shares Outstanding 91.92M shares 91.53M shares 85.58M shares
Diluted Shares Outstanding 94.88M shares 85.58M shares

Balance Sheet

Concept 2012 Q3 2012 Q2 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $50.20M $59.30M $44.10M
YoY Change 45.09% 34.47% -19.82%
Cash & Equivalents $50.22M $59.28M $44.05M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $2.058M $1.029M $500.0K
Prepaid Expenses
Receivables $4.025M $1.536M $1.700M
Other Receivables $3.281M $4.045M $4.900M
Total Short-Term Assets $59.58M $65.89M $51.20M
YoY Change 47.84% 28.69% -12.78%
LONG-TERM ASSETS
Property, Plant & Equipment $16.66M $17.34M $18.90M
YoY Change -9.92% -8.24% 28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.100M $1.100M $1.700M
YoY Change -45.0% -35.29% 112.5%
Total Long-Term Assets $17.80M $18.41M $20.70M
YoY Change -13.18% -11.04% 33.55%
TOTAL ASSETS
Total Short-Term Assets $59.58M $65.89M $51.20M
Total Long-Term Assets $17.80M $18.41M $20.70M
Total Assets $77.38M $84.30M $71.90M
YoY Change 27.27% 17.25% -3.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.400M $4.500M $5.800M
YoY Change -12.0% -22.41% 31.82%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.44M $21.33M $20.30M
YoY Change 11.67% 5.08% 29.3%
LONG-TERM LIABILITIES
Long-Term Debt $2.794M $4.680M $0.00
YoY Change
Other Long-Term Liabilities $52.20M $55.10M $60.30M
YoY Change -12.85% -8.62% 0.5%
Total Long-Term Liabilities $52.17M $55.11M $60.30M
YoY Change -12.9% -8.61% 0.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.44M $21.33M $20.30M
Total Long-Term Liabilities $52.17M $55.11M $60.30M
Total Liabilities $72.61M $76.44M $80.60M
YoY Change -7.15% -5.16% 6.33%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.772M $7.863M -$8.703M
YoY Change
Total Liabilities & Shareholders Equity $77.38M $84.30M $71.90M
YoY Change 27.27% 17.25% -3.1%

Cashflow Statement

Concept 2012 Q3 2012 Q2 2011 Q2
OPERATING ACTIVITIES
Net Income -$5.479M $9.642M -$13.69M
YoY Change -38.26% -170.44% 36.34%
Depreciation, Depletion And Amortization $910.0K $930.0K $920.0K
YoY Change 1.11% 1.09% 21.05%
Cash From Operating Activities -$8.030M $13.12M -$4.820M
YoY Change -1.47% -372.2% -59.15%
INVESTING ACTIVITIES
Capital Expenditures $770.0K $240.0K $1.420M
YoY Change -21.43% -83.1% -43.43%
Acquisitions
YoY Change
Other Investing Activities -$50.00K $0.00 -$30.00K
YoY Change 25.0% -100.0% 50.0%
Cash From Investing Activities -$820.0K -$240.0K -$1.440M
YoY Change -20.39% -83.33% -43.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -140.0K 990.0K -30.00K
YoY Change -3400.0% -200.0%
NET CHANGE
Cash From Operating Activities -8.030M 13.12M -4.820M
Cash From Investing Activities -820.0K -240.0K -1.440M
Cash From Financing Activities -140.0K 990.0K -30.00K
Net Change In Cash -8.990M 13.87M -6.290M
YoY Change -2.07% -320.51% -56.01%
FREE CASH FLOW
Cash From Operating Activities -$8.030M $13.12M -$4.820M
Capital Expenditures $770.0K $240.0K $1.420M
Free Cash Flow -$8.800M $12.88M -$6.240M
YoY Change -3.61% -306.41% -56.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5175000 shares
CY2012Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
5.25
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91923406 shares
CY2011Q2 us-gaap Stockholders Equity
StockholdersEquity
-8703000
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44054000
CY2011Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
89000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
7863000
CY2012Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
55109000
CY2012Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
731000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q2 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1072000
CY2012Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4045000
CY2012Q2 us-gaap Liabilities
Liabilities
76441000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4858000
CY2012Q2 us-gaap Assets
Assets
84304000
CY2012Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
11962000
CY2012Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1536000
CY2012Q2 us-gaap Inventory Net
InventoryNet
1029000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84304000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59280000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21332000
CY2012Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
209000
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
48640000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
65890000
CY2012Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
1789000
CY2012Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4512000
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17342000
CY2012Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4680000
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-11323000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35900000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-26077000
CY2011Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
59189000
CY2011Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
279000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1043000
CY2011Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3837000
CY2011Q4 us-gaap Liabilities
Liabilities
77882000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6121000
CY2011Q4 us-gaap Assets
Assets
51805000
CY2011Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
7540000
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1374000
CY2011Q4 us-gaap Inventory Net
InventoryNet
279000
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51805000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27001000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18693000
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
50923000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
32491000
CY2011Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
1700000
CY2011Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5032000
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18271000
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6566000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18906000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
521000
us-gaap Share Based Compensation
ShareBasedCompensation
521000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4770000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
259000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8811000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4093000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
149000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20590000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3788000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
77000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4016000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8154000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83686094 shares
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2049000
us-gaap Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
16000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19331000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20909000
us-gaap Cost Of Revenue
CostOfRevenue
910000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
73000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83686094 shares
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-652000
us-gaap Revenues
Revenues
4892000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
77000
us-gaap Gross Profit
GrossProfit
472000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1410000
us-gaap Net Income Loss
NetIncomeLoss
-18741000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
165000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
149000
plx Depreciation Amortization And Asset Impairment
DepreciationAmortizationAndAssetImpairment
1801000
plx Supplemental Offering And Stock Issuance Costs
SupplementalOfferingAndStockIssuanceCosts
60000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
1995000
plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
15590000
plx Other Gains Losses
OtherGainsLosses
-3510000
plx Proceeds From Issuance Of Common Stock Net Of Expenses
ProceedsFromIssuanceOfCommonStockNetOfExpenses
20650000
plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
3741000
dei Trading Symbol
TradingSymbol
PLX
dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001006281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Operating Income Loss
OperatingIncomeLoss
3555000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3759000
us-gaap Share Based Compensation
ShareBasedCompensation
3759000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2128000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1086000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6843000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1091000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3546000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25388000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1047000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
32279000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5133000
us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
133000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92670033 shares
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1055000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
462000
us-gaap Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
14000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19391000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26564000
us-gaap Cost Of Revenue
CostOfRevenue
4599000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
3000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89702496 shares
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
750000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2967537 shares
us-gaap Revenues
Revenues
29974000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
44000
us-gaap Gross Profit
GrossProfit
24387000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1780000
us-gaap Net Income Loss
NetIncomeLoss
3738000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
183000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-37000
plx Depreciation Amortization And Asset Impairment
DepreciationAmortizationAndAssetImpairment
1860000
plx Supplemental Offering And Stock Issuance Costs
SupplementalOfferingAndStockIssuanceCosts
150000
plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
1357000
plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
15699000
plx Other Gains Losses
OtherGainsLosses
-988000
plx Proceeds From Issuance Of Common Stock Net Of Expenses
ProceedsFromIssuanceOfCommonStockNetOfExpenses
25478000
plx Number Of Subsidiaries
NumberOfSubsidiaries
2 Entity
plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
3692000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25388000
CY2012Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1780000
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13868000
CY2011Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1799000
CY2011Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85579534 shares
CY2011Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8768000
CY2011Q2 us-gaap Cost Of Revenue
CostOfRevenue
132000
CY2011Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85579534 shares
CY2011Q2 us-gaap Revenues
Revenues
764000
CY2011Q2 us-gaap Gross Profit
GrossProfit
-4750000
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-13689000
CY2011Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
179000
CY2011Q2 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
7319000
CY2011Q2 plx Other Gains Losses
OtherGainsLosses
-5382000
CY2011Q2 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
1449000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
9620000
CY2012Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3504000
CY2012Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94881167 shares
CY2012Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10544000
CY2012Q2 us-gaap Cost Of Revenue
CostOfRevenue
3279000
CY2012Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91526224 shares
CY2012Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3354943 shares
CY2012Q2 us-gaap Revenues
Revenues
26113000
CY2012Q2 us-gaap Gross Profit
GrossProfit
21979000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
9642000
CY2012Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
22000
CY2012Q2 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
8855000
CY2012Q2 plx Other Gains Losses
OtherGainsLosses
-855000
CY2012Q2 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
1689000
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
60000000

Files In Submission

Name View Source Status
0001144204-12-042862-index-headers.html Edgar Link pending
0001144204-12-042862-index.html Edgar Link pending
0001144204-12-042862.txt Edgar Link pending
0001144204-12-042862-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
plx-20120630.xml Edgar Link completed
plx-20120630.xsd Edgar Link pending
plx-20120630_cal.xml Edgar Link unprocessable
plx-20120630_def.xml Edgar Link unprocessable
plx-20120630_lab.xml Edgar Link unprocessable
plx-20120630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v318251_10q.htm Edgar Link pending
v318251_ex31-1.htm Edgar Link pending
v318251_ex31-2.htm Edgar Link pending
v318251_ex32-1.htm Edgar Link pending
v318251_ex32-2.htm Edgar Link pending